Sclerotherapy
PreclinicalSmall molecule
Sclerotherapy is one of 72 small molecule programs targeting Granuloma. It is currently in Preclinical.
3
Indications
4
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Marcaine
IInnocoll
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Kenalog
BBassett Healthcare
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Granuloma1 trial
Effect of Laser and Sclerotic Agent in the Treatment of Oral Granuloma
Not yet recruiting·—·N/A·NCT06639230·20 enrolled
Hereditary Hemorrhagic Telangiectasia1 trial
Hemorrhoid1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sclerotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Minnesota